Deal Process

Our deal selection process is meticulously designed to identify, evaluate, and fund projects that expedite the development of new, safe treatments, ensuring tangible benefits for patient stakeholders.

Areas of Focus

Elata takes a top-down approach to its development process, meaning our focus is primarily applied to early-stage efforts followed by strong emphasis on downstream (clinical) patient outcomes. This is a process also known as translational medicine or, in our case, translational psychiatry.

Focusing on downstream patient outcomes and using clinical data to supplement our efforts is a de-risking mechanism we have implemented. As psychiatry is heavily nuanced and difficult, it is apparent that working around clinically validated mechanisms of action and results is a way to decrease the likelihood of any failure.

Elata initiates programs that advance psychiatry, with a specific focus on precision, and are broken up based on the following criteria:

1. Computational chemistry/psychiatry platforms supporting patient stratification, biomarkers, adjunct therapeutics, and drug delivery platforms.

2. Novel molecules, with a focus on drugs tailored for areas of high unmet patient need, such as those without pre-existing treatments available. We aim to craft a diversified portfolio over time which includes small molecules with clinically-validated mechanisms of action (MoA).

3. Drug repositioning including filings for method of use (MoU) patents, and combination drugs (fixed-dose combinations; FDC's). To craft a diversified portfolio, we plan on implementing sophisticated de-risking strategies that allow us to become economically sustainable and fund projects that are on the bleeding-edge of neuropsychiatry.

Process

Elata's Development team and/or contributors will meticulously evaluate research proposals based on predefined criteria. The initial screening process will assess alignment with the current call for proposals, the Elata mission, and the proposal's readiness level for advancement. Additionally, the status of intellectual property will be thoroughly evaluated.

Proposals that pass the initial screening will undergo internal and external board review to strengthen or refine the initial assessment. Following this, a community presentation will be held, where members will discuss and decide whether to recommend the study for funding.

If approved, the project will proceed to the community vote, legal contract establishment, funding transfer, and project execution by the research laboratory.

Upon successful project execution and hypothesis confirmation, Elata will collaborate with the research team to determine the next steps and necessary resources for advancing the project. This may involve further research, clinical trials, or partnerships with pharmaceutical companies.

Channels for sourcing deals include releasing request for proposals (RFPs) to neuropsychiatry consortiums/NGOs, patent databases, and leveraging our network of Scientific Advisors and collaborators to uncover funding opportunities before they make it into journals. This will broaden our access to exclusive IP and funding opportunities.